The investigational therapy, vesleteplirsen, had been positioned as an updated version of Sarepta’s original exon 51-skipping ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Year-over-year BioSpace data shows there are fewer job postings live on the website and far more competition for them.

In this episode of Denatured, Lori and guests from Teva Pharmaceuticals and TOWER Capital discuss the opportunties, regulatory challenges and uncertainty surrounding AI.

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Analyst reactions to Donald Trump’s election victory were mixed Wednesday, with potential positives including an FTC that is ...

Novo Nordisk’s total revenue in the third quarter missed analysts’ expectations but sales of weight loss drug Wegovy exceeded the consensus forecast. Still, the Danish drugmaker narrowed its full-year ...